USE(S)
relieves:
- •
- diarrhea
- •
- heartburn
- •
- indigestion
- •
- nausea
- •
- upset stomach associated with these symptoms
WARNINGS
Reye's Syndrome: Children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not use this product. When using this product, if changes in behaviour with nausea and vomiting occur, consult a doctor because these symptoms could be an early sign of Reye's Syndrome, a rare but serious illness.
Allergy alert: Contains salicylate. Do not take if you are
- •
- allergic to salicylates (including aspirin)
- •
- taking other salicylate products
ASK A DOCTOR OR PHARMACIST BEFORE USE IF YOU ARE
taking any drug for
- •
- anticoagulation (thinning of the blood)
- •
- diabetes
- •
- gout
- •
- arthritis
STOP USE AND ASK DOCTOR IF
- •
- symptoms get worse
- •
- ringing in the ears or loss of hearing occurs
- •
- diarrhea lasts more than 2 days
KEEP OUT OF REACH OF CHILDREN
In case of overdose, get medical help or contact a Poison Control Center (1-800-222-1222) immediately.
DIRECTIONS
- •
- chew or dissolve in mouth
- •
- adults and children 12 years and over: 2 tablets every 1/2 to 1 hour as needed
- •
- do not take more than 8 doses (16 tablets) in 24 hours
- •
- children under 12 years: ask a doctor
- •
- drink plenty of clear fluids to help prevent dehydration caused diarrhea
OTHER INFORMATION
- •
- each tablet contains:
- •
- sodium less than 1 mg
- •
- salicylate 102 mg
- •
- very low sodium
- •
- avoid excessive heat (over 104oF or 40oC)
- •
- TAMPER EVIDENT: Do not use if individual compartments are torn on open.
INACTIVE INGREDIENTS
calcium carbonate, D&C red 27 aluminum lake, flavor, magnesium stearate, mannitol, pregelatinized starch, saccharin sodium
PRINCIPAL DISPLAY PANEL
MAJOR
NDC 68788-8239-3
*Compare to the active ingredient in Pepto-Bismol®
Bismuth Subsalicylate 262 mg
Upset Stomach Reliever / Anti-diarrheal
Soothing, coating action provides fast relief for
heartburn, indigestion
nausea, upset stomach
and diarrhea
30 Chewable Tablets
Relabeled By: Preferred Pharmaceuticals Inc.
